Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by MOESCH, C.
Right arrow Articles by LEROUX-ROBERT, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MOESCH, C.
Right arrow Articles by LEROUX-ROBERT, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 Oxford University Press

research-article

Calcium Oxalate Crystalluria in Elderly Patients and Treatment with Naftidrofuryl Oxalate

CHRISTIAN MOESCH, JEAN-PIERRE CHARMES*,, FRANÇOIS BOUTHIER and CLAUDE LEROUX-ROBERT

Service de Néphrologie, Centre Hospitalier et Universitaire 87042 Limoges Cedex, France
Département de Médecine Gérontologique, Centre Hospitalier et Universitaire 87042 Limoges Cedex, France

* Address correspondence to J.-P. Charmes, MD

Crystalluria is important in the evaluation of patients with urinary stone and is more frequently encountered in elderly than in younger adults. After noting that calcium oxalate monohydrate crystalluria was higher in elderly patients, we undertook a study to determine if oral treatment with naftidrofuryl oxalate, a drug frequently prescribed for elderly patients in France, was associated with crystalluria.

The presence of early morning crystalluria was assessed in non-stone-forming patients hospitalized in a geriatric department. We studied 251 patients without a history of nephrolithiasis (mean age: 81.6 ± 8.5 years) of whom 49 had been treated orally with naftidrofuryl oxalate at a mean dosage of 485 ± 120 mg/24 h. We identified and quantified the crystals in one early morning urine sample kept at room temperature. The frequency of crystalluria in elderly patients without stones who were not taking naftidrofuryl oxalate was 31.7% compared with only 6% in the general adult population. In this group, mainly calcium phosphate crystals were found. In patients who received naftidrofuryl oxalate, the frequency of crystalluria was 51% of which the major component was calcium oxalate monohydrate and not calcium phosphate. Naftidrofuryl oxalate may enhance crystal formation in elderly patients. This should be taken into account, particularly when other predisposing factors for nephrolithiasis are present, and a preventive increase in fluid intake considered.

Revision received February 23, 1995.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
T De Backer, R Vander Stichele, P Lehert, and L Van Bortel
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data
BMJ, March 10, 2009; 338(mar10_1): b603 - b603.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.